Biskit

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

Retrieved on: 
Friday, October 27, 2023
Attention, US, Toronto Stock Exchange, OTC Markets Group, MDNA, Biskit, CFO, TSX, Calendar, Cryptocurrency

The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by executing a reverse stock split.

Key Points: 
  • The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by executing a reverse stock split.
  • The Company’s common shares will continue to trade on the Toronto Stock Exchange (“TSX”).
  • Following the delisting of the Company’s common shares on the Nasdaq, the Company will also seek to have its common shares traded on the OTC Markets as soon as possible thereafter.
  • In connection with the Nasdaq delisting and in effort to further preserve capital, the Board decided to reduce the size of its management team as well as its presence in the United States.

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Tuesday, October 3, 2023
Stimulator of interferon genes, Bifunctional, AACR, Biskit, Syngenic, Survival, Immunotherapy, MDNA, CD8, Synergism, TSX, Neoplasm, Poster, PD-1, IL-2R, Conference, Pharmaceutical industry, Vaccine

TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

Key Points: 
  • TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.
  • “We believe that our dual-functioning BiSKIT candidates, such as MDNA223, are more potent and selective and may have an increased capacity to induce superior CD8+ T cell responses against tumor cells.
  • The sum of encouraging preclinical data on MDNA223 highlights the potential of Medicenna’s BiSKIT platform to broadly delivery effective therapy to otherwise challenging-to-treat ‘cold’ tumors.
  • Copies of the poster will be posted to the “ Events and Presentations ” page of Medicenna’s website following the conclusion of the meeting.

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee 

Retrieved on: 
Tuesday, August 8, 2023
University, Drug development, Biskit, MBBS, CSO, Calendar, Cancer, MDNA, Inflammation, Autoimmunity, Bachelor of Science, Glioblastoma, Patient, Principal, University of Oxford, Pharmaceutical industry, Medical device

TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee (“DAC”), a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy.

Key Points: 
  • TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee (“DAC”), a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy.
  • “We are pleased to welcome Dr. Arash Yavari as the Chair of our Development Advisory Committee,” said Dr. Fahar Merchant, President and CEO of Medicenna.
  • “We have been working closely with Dr. Yavari on MDNA11 for the past two years and have appreciated his considerable expertise in drug development.
  • Dr. Yavari holds a BSc and MBBS from the University of London, and a DPhil from the University of Oxford.

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent

Retrieved on: 
Thursday, January 5, 2023
Cancer, Pembrolizumab, CTLA4, IP, Patent, Biskit, Toxicity, Patient, MDNA, Immunotherapy, Intellectual property, Bifunctional, Cell, Pharmaceutical industry

TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1.” The patent provides intellectual property (IP) protection for methods of treating cancer with an IL-2 Superkine such as MDNA11 and a PD1 (for example, pembrolizumab), PDL1 or CTLA-4 checkpoint inhibitor in combination, as planned in the on-going ABILITY clinical trial, or as a single agent using our BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform. The patent’s term extends into at least 2039 without accounting for any potential extensions.

Key Points: 
  • The patent’s term extends into at least 2039 without accounting for any potential extensions.
  • MDNA223 is a preclinical-stage BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
  • Both MDNA11 and MDNA109FEAA are designed to selectively stimulate anti-cancer immune cells without activating cells associated with pro-tumor immune pathways or extreme toxicity.
  • This newly issued patent adds to Medicenna’s portfolio of issued and filed patents and applications providing protection for the Company’s innovative IL‐2 Superkines, including MDNA11, in the U.S., Europe, Japan, China, Canada, India, and Australia.

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 4, 2022
MSD, Patient, EMA, FDA, Population, MD, United States patent law, Research, Cytokine, Annual report, Patent, Melanoma, SD, SITC, Company, CD122, GLOBE, Intellectual property, IND, NK, Toxic leukoencephalopathy, Immunotherapy, CEO, Renal cell carcinoma, Mission statement, Forward-looking statement, ID, PD, Society, Pharmacokinetics, EDGAR, Doctor of Philosophy, Method, 1836 U.S. Patent Office fire, MDNA, Annual general meeting, Biskit, Pancreatic cancer, International Cytokine & Interferon Society, Safety, GBM, CD25, Brain, Merck & Co., PR, USD, NASDAQ, IP, Pembrolizumab, United, News, SEDAR, GMP, Leukemia, Bifunctional, Mobile phone, Pharmaceutical industry, Vaccine, Security (finance), Cryptocurrency, Audit, Merck

TORONTO and HOUSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2022. All dollar amounts are in Canadian currency unless otherwise noted.

Key Points: 
  • The confirmatory scan for this patient showed further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy.
  • All patients in the trials dose escalation phase are treated with MDNA11 monotherapy via intravenous infusion every two weeks.
  • Under the terms of the agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA.
  • Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

Retrieved on: 
Thursday, September 22, 2022
Half-life, P69, Biskit, Type, CD25, FDA, Bifunctional, Cancer, Company, Macrophage, Neoplasm, GBM, CD122, Melanoma, News, Cytokine, Forward-looking statement, Program, Type 2, Tams, NK, Colon, International Cytokine & Interferon Society, Breast cancer, Growth, CEO, TF-1, Serum, Doctor of Philosophy, TME, MDNA, NASDAQ, Immunotherapy, MDSC, GLOBE, Skin, Brain, EMA, Vaccine, Pharmaceutical industry, Online shopping, FC

TORONTO and HOUSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced presentation of data from two preclinical programs that demonstrate the anti-tumor activity of the Company’s anti-PD1-IL-2 (aka MDNA223) BiSKIT (Bi-functional SuperKines for ImmunoTherapy) and long-acting IL-4/IL-13 super-antagonist (aka MDNA413). The data are featured in two separate poster presentations at the 10th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2022), which is taking place both virtually and in-person at the Hilton Waikoloa Village, in Big Island, Hawaii.

Key Points: 
  • In addition, data on our long-acting MDNA413 Superkine demonstrated its potential to reverse the immunosuppressive tumor microenvironment that are known to limit the efficacy of cancer immunotherapies.
  • Poster P110 includes preclinical data from in vitro and in vivo studies of MDNA223, a next generation BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
  • In vivo murine data showed MDNA223 exhibiting a prolonged pharmacodynamic response extending beyond the duration of pharmacokinetic exposure.
  • Poster P69 includes preclinical data from in vitro and in vivo studies of Fc-MDNA413, a novel, long-acting IL-4/IL-13 Superkine.

Medicenna Reports First Quarter Fiscal 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, August 15, 2022
CEO, GLOBE, R, MDNA, Clinical trial, TSX, Toxicity, Research, Renal cell carcinoma, Bifunctional, Patient, G&A, News, MD, Immunosuppression, SEDAR, Drug development, GMP, Safety, Immunotherapy, Biskit, ID, Pharmacokinetics, CD25, Forward-looking statement, EDGAR, Eosinophil, GBM, Mission statement, PK, Sarcoma, Brain, Melanoma, FDA, UPR, RECIST, Pharmacodynamics, NK, PD, IND, Review, Calendar, Company, Pancreatic cancer, Cytokine, NASDAQ, EDT, CD122, EMA, Pharmaceutical industry, Vaccine, Audit

-- Management Hosting Conference Call And Webcast Today At 8:30 am EDT

Key Points: 
  • TORONTO and HOUSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the quarter ended June 30, 2022.
  • We are off to a solid start in fiscal 2023 with a stronger balance sheet and promising anti-tumor activity of MDNA11 monotherapy in the ABILITY study, said Dr.Fahar Merchant, President and CEO of Medicenna.
  • As a result, the preliminary data from this scan are subject to change and not predictive of the final results.
  • Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

Retrieved on: 
Thursday, August 11, 2022
Wainwright Securities Inc. v. Wall Street Transcript Corp., U.S. Securities and Exchange Commission, Telephone, Madison Avenue, SEC filing, Exercise, Canadian Securities Administrators, Forward-looking statement, GLOBE, MDNA, SEC, TSX, Sale, LLC, Company, Floor, Attention, Register, NASDAQ, Guggenheim Partners, News, Biskit, Offering, Registration statement, SEDAR, Security (finance), Pharmaceutical industry, Online shopping

Pursuant to the Offering, the Company issued a total of 13,333,334 Units.

Key Points: 
  • Pursuant to the Offering, the Company issued a total of 13,333,334 Units.
  • Each Unit is comprised of one common share and one common share purchase warrant (each whole common share purchase warrant, a Warrant).
  • The Offering was made pursuant to a registration statement on FormF-10 (File No.
  • The Offering Documents contain important detailed information about the Offering.

Medicenna Announces Pricing of US$20 Million Public Offering of Units

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, Telephone, Madison Avenue, SEC filing, Canadian Securities Administrators, Forward-looking statement, GLOBE, MDNA, SEC, TSX, Toronto Stock Exchange, Sale, LLC, Nasdaq, Company, Floor, Attention, Register, NASDAQ, Guggenheim Partners, News, Biskit, Offering, Registration statement, SEDAR, Security (finance), Pharmaceutical industry, Online shopping

The gross proceeds to the Company from the Offering are expected to be approximately US$20 million, before deducting underwriting discounts and commission and other expenses.

Key Points: 
  • The gross proceeds to the Company from the Offering are expected to be approximately US$20 million, before deducting underwriting discounts and commission and other expenses.
  • Guggenheim Securities, LLC is acting as sole book-running manager for the Offering.
  • Bloom Burton Securities Inc. is acting as co-manager for the Offering.
  • The Offering Documents will contain important detailed information about the Offering.

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Telephone, Madison Avenue, SEC filing, Exercise, Warrant, Canadian Securities Administrators, Forward-looking statement, GLOBE, MDNA, SEC, TSX, Toronto Stock Exchange, Sale, LLC, Nasdaq, Company, Floor, Attention, Register, Guggenheim Partners, News, Biskit, Offering, Registration statement, SEDAR, Security (finance), Pharmaceutical industry

TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or theCompany) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the Units) in the United States (theOffering).

Key Points: 
  • TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or theCompany) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the Units) in the United States (theOffering).
  • The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing.
  • There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
  • Guggenheim Securities, LLC is acting as sole book-running manager for the Offering.